Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 2, 2010, Pages 131-137

  Bertolini, Francesco ^a   Marighetti, Paola ^a   Shaked, Yuval ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Angiogenesis; Endothelial progenitors; Oncology endothelial cells

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CELL MARKER; CHEMOKINE; CYCLOPHOSPHAMIDE; DALTEPARIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GROWTH FACTOR; IRINOTECAN; METHOTREXATE; MOTESANIB; PACLITAXEL; PREDNISONE; SEMAXANIB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TUMOR MARKER; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB;

ADVANCED CANCER; APOPTOSIS; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEMATOPOIETIC CELL; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MONOTHERAPY; NEUROENDOCRINE TUMOR; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SOFT TISSUE SARCOMA; STEM CELL; TUMOR VASCULARIZATION; CANCER THERAPY; DISEASE MARKER; MEDICAL DECISION MAKING; PATIENT IDENTIFICATION; PATIENT INFORMATION;

ANGIOGENESIS INHIBITORS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATIENT SELECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78649465366     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.05.004     Document Type: Review

References (64)

1. Kerbel R.S. Tumor angiogenesis. New Engl. J. Med. 2008, 358:2039-2049.
2. Jain R.K., Duda D.G., Willett C.G., Sahani D.V., Zhu A.X., Loeffler J.S., Batchelor T.T., Sorensen A.G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009, 6:327-338.
3. Murukesh N., Dive C., Jayson G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 2010, 102:8-18.
4. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
5. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
6. Bergers G., Hanahan D. Models of resistance of anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
7. Bertolini F., Mancuso P., Braidotti P., Shaked Y., Kerbel R.S. The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochim. Biophys. Acta 2009, 1796:27-32.
8. Shaked Y., Voest E.E. Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?. Biochim. Biophys. Acta 2009, 1796:1-4.
9. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
10. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
11. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 2002, 94:883-893.
12. Blann A.D., Woywodt A., Bertolini F., Bull T.M., Buyon J.P., Clancy R.M., Haubitz M., Hebbel R.P., Lip G.Y., Mancuso P., Sampol J., Solovey A., Dignat-George F. Circulating endothelial cells. Biomarker of vascular disease. Thromb. Haemost. 2005, 93:228-235.
13. Bertolini F., Shaked Y., Mancuso P., Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 2006, 6:835-845.
14. Hirschi K.K., Ingram D.A., Yoder M.C. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1584-1595.
15. Yoder M.C., Ingram D.A. The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process?. Biochim. Biophys. Acta 2009, 1796:50-54.
16. Gao D., Nolan D., McDonnell K., Vahdat L., Benezra R., Altorki N., Mittal V. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim. Biophys. Acta 2009, 1796:33-40.
17. Goon P.K., Lip G.Y., Stonelake P.S., Blann A.D. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 2009, 11:771-779.
18. Mancuso P., Antoniotti P., Quarna J., Calleri A., Rabascio C., Tacchetti C., Braidotti P., Wu H.K., Zurita A.J., Saronni L., Cheng J.B., Shalinsky D.R., Heymach J.V., Bertolini F. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin. Cancer Res. 2009, 15:267-273.
19. Seandel M., Butler J., Lyden D., Rafii S. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. Cancer Cell 2008, 13:181-183.
20. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., Oz M.C., Hicklin D.J., Witte L., Moore M.A., Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95:952-958.
21. Madlambayan G.J., Butler J.M., Hosaka K., Jorgensen M., Fu D., Guthrie S.M., Shenoy A.K., Brank A., Russell K.J., Otero J., Siemann D.W., Scott E.W., Cogle C.R. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood 2009, 114:4310-4319.
22. Calleri A., Bono A., Bagnardi V., Quarna J., Mancuso P., Rabascio C., Dellapasqua S., Campagnoli E., Shaked Y., Goldhirsch A., Colleoni M., Bertolini F. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin. Cancer Res. 2009, 15:7652-7657.
23. Sorensen A.G. Magnetic resonance as a cancer imaging biomarker. J. Clin. Oncol. 2006, 24:3274-3281.
24. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 2008, 14:1407-1412.
25. Heymach J.V., Desai J., Manola J., Davis D.W., McConkey D.J., Harmon D., Ryan D.P., Goss G., Quigley T., Van den Abbeele A.D., Silverman S.G., Connors S., Folkman J., Fletcher C.D., Demetri G.D. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res. 2004, 10:5732-5740.
26. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., Lehman M., Adams B.J., Bello C.L., DePrimo S.E., Baum C.M., Miller K.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26:1810-1816.
27. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., Hutson T.E., Margolin K., Harmon C.S., DePrimo S.E., Kim S.T., Chen I., George D.J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26:3743-3748.
28. Kiura K., Nakagawa K., Shinkai T., Eguchi K., Ohe Y., Yamamoto N., Tsuboi M., Yokota S., Seto T., Jiang H., Nishio K., Saijo N., Fukuoka M. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J. Thorac. Oncol. 2008, 3:386-393.
29. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., Shaked Y., Mancuso P., Goldhirsch A., Rocca A., Pietri E., Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 2008, 26:4899-4905.
30. Ko A.H., Venook A.P., Bergsland E.K., Kelley R.K., Korn W.M., Dito E., Schillinger B., Scott J., Hwang J., Tempero M.A. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother.. Pharmacol. 2010, [Electronic publication ahead of print].
31. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., Flockhart D.A., Hancock B., Davidson N., Gralow J., Dickler M., Perez E.A., Cobleigh M., Shenkier T., Edgerton S., Miller K.D. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 2008, 26:4672-4678.
32. Schultheis A.M., Lurje G., Rhodes K.E., Zhang W., Yang D., Garcia A.A., Morgan R., Gandara D., Scudder S., Oza A., Hirte H., Fleming G., Roman L., Lenz H.J. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 2008, 14:7554-7563.
33. Kopetz S., Hoff P.M., Morris J.S., Wolff R.A., Eng C., Glover K.Y., Adinin R., Overman M.J., Valero V., Wen S., Lieu C., Yan S., Tran H.T., Ellis L.M., Abbruzzese J.L., Heymach J.V. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010, 28:453-459.
34. Flaherty K.T., Rosen M.A., Heitjan D.F., Gallagher M.L., Schwartz B., Schnall M.D., O'Dwyer P.J. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol. Ther. 2008, 7:496-501.
35. Wilson P.M. Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor in patients enrolled in CONFIRM1 and CONFIRM2. ASCO (Meeting Abstracts) 2008, 26:4002.
36. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
37. Scartozzi M., Galizia E., Chiorrini S., Giampieri R., Berardi R., Pierantoni C., Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann. Oncol. 2009, 20:227-230.
38. Dahlberg S.E., Sandler A.B., Brahmer J.R., Schiller J.H., Johnson D.H. Clinical course of advanced bon-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J. Clin. Oncol. 2010, [Electronic publication ahead of print].
39. Maitland M.L., Moshier K., Imperial J., Kasza K.E., Karrison T., Elliott W., Undevia S.D., Stadler W., Desai A.A., Ratain M.J. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. J. Clin. Oncol. (Meeting Abstracts) 2006, 24:2035.
40. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., Hewitt S.M., Berman A., Steinberg S.M., Liewehr D.J., Plehn J., Doshi A., Thomasson D., McCarthy N., Koeppen H., Sherman M., Zujewski J., Camphausen K., Chen H., Swain S.M. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 2006, 24:769-777.
41. Mancuso P., Colleoni M., Calleri A., Orlando L., Maisonneuve P., Pruneri G., Agliano A., Goldhirsch A., Shaked Y., Kerbel R.S., Bertolini F. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006, 108:452-459.
42. Beaudry P., Force J., Naumov G.N., Wang A., Baker C.H., Ryan A., Soker S., Johnson B.E., Folkman J., Heymach J.V. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin. Cancer Res. 2005, 11:3514-3522.
43. Norden-Zfoni A., Desai J., Manola J., Beaudry P., Force J., Maki R., Folkman J., Bello C., Baum C., DePrimo S.E., Shalinsky D.R., Demetri G.D., Heymach J.V. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 2007, 13:2643-2650.
44. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffler J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
45. Roodhart J.M., Langenberg M.H., Vermaat J.S., Lolkema M.P., Baars A., Giles R.H., Witteveen E.O., Voest E.E. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 2010, 12:87-94.
46. Cacheux W., Boisserie T., Staudacher L., Vignaux O., Dousset B., Soubrane O., Terris B., Mateus C., Chaussade S., Goldwasser F. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann. Oncol. 2008, 19:1659-1661.
47. Norden A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., Ciampa A.S., Ebbeling L.G., Levy B., Drappatz J., Kesari S., Wen P.Y. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
48. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study. J. Clin. Oncol. 2008, 26:5326-5334.
49. Ellis L.M., Haller D.G. Bevacizumab beyond progression: does this make sense?. J. Clin. Oncol. 2008, 26:5313-5315.
50. Mross K., Drevs J., Muller M., Medinger M., Marme D., Hennig J., Morgan B., Lebwohl D., Masson E., Ho Y.Y., Gunther C., Laurent D., Unger C. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer 2005, 41:1291-1299.
51. Thomas A.L., Morgan B., Horsfield M.A., Higginson A., Kay A., Lee L., Masson E., Puccio-Pick M., Laurent D., Steward W.P. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. 2005, 23:4162-4171.
52. Conrad C., Friedman H., Reardon D., Provenzale J., Jackson E., Serajuddin H., Laurent D., Chen B., Yung W.K.A. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. (Meetings Abstracts) 2004, 22:1512.
53. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M.A., Mross K., Ball H.A., Lee L., Mietlowski W., Fuxuis S., Unger C., O'Byrne K., Henry A., Cherryman G.R., Laurent D., Dugan M., Marme D., Steward W.P. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003, 21:3955-3964.
54. Vecchiarelli-Federico L.M., Cervi D., Haeri M., Li Y., Nagy A., Ben-David Y. Vascular endothelial growth factor-a positive and negative regulator of tumor growth. Cancer Res. 2010, 70:863-867.
55. Siegel A.B., Cohen E.I., Ocean A., Lehrer D., Goldenberg A., Knox J.J., Chen H., Clark-Garvey S., Weinberg A., Mandeli J., Christos P., Mazumdar M., Popa E., Jr R.S., Brown S.Rafii, Schwartz J.D. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 2008, 26:2992-2998.
56. Spratlin J.L., Cohen R.B., Eadens M., Gore L., Camidge D.R., Diab S., Leong S., O'Bryant C., Chow L.Q., Serkova N.J., Meropol N.J., Lewis N.L., Chiorean E.G., Fox F., Youssoufian H., Rowinsky E.K., Eckhardt S.G. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. J. Clin. Oncol. 2010, 28:780-787.
57. Wong N.S., Buckman R.A., Clemons M., Verma S., Dent S., Trudeau M.E., Roche K., Ebos J., Kerbel R., DeBoer G.E., Sutherland D.J.A., Emmenegger U., Slingerland J., Gardner S., Pritchard K.I. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide. Twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J. Clin. Oncol. 2010, 28:723-730.
58. Bello C., Deprimo S.E., Friece C., Smeraglia J., Sherman L., Tye L., Baum C., Meropol N.J., Lenz H., Kulke M.H. Analysis of circulating biomarkers of sunitinib maleate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. Proc. Am. Soc. Clin. Oncol. 2006, 24:4045a.
59. Rosen L.S., Kurzrock R., Mulay M., Van Vugt A., Purdom M., Ng C., Silverman J., Koutsoukos A., Sun Y.N., Bass M.B., Xu R.Y., Polverino A., Wiezorek J.S., Chang D.D., Benjamin R., Herbst R.S. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2007, 25:2369-2376.
60. Hanrahan E.O., Lin H.Y., Kim E.S., Yan S., Du D.Z., McKee K.S., Tran H.T., Lee J.J., Ryan A.J., Langmuir P., Johnson B.E., Heymach J.V. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:193-201.
61. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I., Mross K., Medinger M., Lee L., Pinheiro J., Wood J., Thomas A.L., Unger C., Henry A., Steward W.P., Laurent D., Lebwohl D., Dugan M., Marme D. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann. Oncol. 2005, 16:558-565.
62. Jr Lara P.N., Quinn D.I., Margolin K., Meyers F.J., Longmate J., Frankel P., Mack P.C., Turrell C., Valk P., Rao J., Buckley P., Wun T., Gosselin R., Galvin I., Gumerlock P.H., Lenz H.J., Doroshow J.H., Gandara D.R. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin. Cancer Res. 2003, 9:4772-4781.
63. Stopeck A., Sheldon M., Vahedian M., Cropp G., Gosalia R., Hannah A. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res. 2002, 8:2798-2805.
64. Hahn O.M., Yang C., Medved M., Karczmar G., Kistner E., Karrison T., Manchen E., Mitchell M., Ratain M.J., Stadler W.M. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J. Clin. Oncol. 2008, 26:4572-4578.